A classification system must have relevance and importance in the clinical management, should be easily applicable and enable uniformity in reporting. Various lymphoma classifications have been formulated on the basis of morphology (Rappaport), 1 clinical features (Working formulation) 1 and on cell lineage and differentiation (Keil, Lukes and Collins). 1 During 1970s and 1980s, popular lymphoma classifications were Lukes and Collins and Working formulation in USA, whereas Keil classification was popular in Europe. 1 Pathologists and oncologists from the rest of the world followed either one depending on their training and on the availability of ancillary techniques including immunohistochemistry. It was followed by the Revised European and American Lymphoma classification from the International Lymphoma Study Group, [2] [3] [4] an informal group of 19 hematopathologists mainly from Europe and USA. World Health Organization (WHO) classification is an updated version of the Revised European and American Lymphoma classification and include myeloid, histiocytic and mast cell neoplasm. 5 WHO classification project included pathologists, hematologists and oncologists. Most of these were from USA and Europe, including two from Asia (one each from Hong Kong and Japan). [3] [4] [5] There was no participation from the rest of the Asia and Africa.
For acute leukemia, French-American-British system of classification 6 is still in vogue in many centers with limited resources for flow cytometry and molecular diagnostics. Lack of availability of molecular techniques has resulted in paucity of published data on the basis of WHO classification from two-third of the world. Though the present WHO classification system is evidence-based and needs to be followed for best clinical practice, it is impractical in many countries. Such classifications, which are practiced mainly in Europe and USA should preferably be labeled as French-American-British/Revised European and American Lymphoma classification as they defeat the basic mandate of WHO classification, which has a purpose to promote the appropriate selection of classifications in the health field across the world. Also many new cases of acute leukemia first get treated by local physicians and even by quacks by steroids and blood transfusion in the developing countries. It may lead to change in the phenotype and the genotype of the disease. There is no mention of partially treated acute leukemia subtype in the present WHO classification. Such cases form a significant percentage of acute leukemia cases in developing countries as seen in our practice. There is a vast difference in the pattern of diseases, 7 and also the infrastructure available in different parts of the world to diagnose hematolymphoid malignancies. Advisory committee of WHO classifications must have representation from developed as well as developing world so to devise a system, which must be easy to follow and as inclusive as possible. Perhaps WHO can advocate two systems, one ideal (which can be implemented in the laboratories of the developed countries) and the other that advocates a minimum data that is required in the report for effective clinical management (to be followed in low and medium resource countries). The laboratories in the developing countries can aspire and shall be encouraged to use the ideal system as much as possible. Immunohistochemistry and flow cytometry are available in most of the hematopathology laboratories; however, molecular genetics is still available in extremely few laboratories. The CEBPA gene, encoding the CCAAT/enhancer-binding protein-a (C/EBPa) transcription factor, is mutated in approximately 10% of acute myelogenous leukemia (AML). 1 The discovery of these mutations confirmed a long-standing hypothesis that the disruption of genes regulating differentiation is a critical step in leukemogenesis. 2 The importance of C/EBPa in myeloid differentiation was first recognized due to its pivotal role in the regulation of myeloid-specific genes; however, the most compelling evidence came from studies on knockout mice, its ablation resulting in a differentiation block at the myeloblast stage. 3 More recent data have pinpointed the block at the transition from a common myeloid progenitor (CMP) to a granulocyte-macrophage progenitor (GMP), but this can be overcome by stimulation with GM colony-stimulating factor or interleukin-3. These cytokines presumably activate an alternative pathway of 'emergency' granulopoiesis, involving C/EBPb. 3 Unfortunately, these cytokines are unable to reverse the differentiation block observed in human AML, 4 suggesting distinct control mechanisms in human myelopoiesis and/or a more complex mechanism by which differentiation is blocked in AML. In favor of the former hypothesis, we have shown earlier that the ectopic expression of a C/EBPa mutant found in AML patients has different effects in mouse versus human hematopoietic cells. 5 In the study presented here, we have investigated possible mechanisms behind this difference.
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The majority of CEBPA mutations results in the translation of an N-terminal truncated C/EBPa protein, termed p30, that lacks two of three transactivation elements that are important for recruiting 4 cells per ml in the presence of hSCF (50 ng/ml), hIL-3 (50 ng/ml) and hGM-CSF (50 ng/ml) to support differentiation were evaluated after 7 and 14 days by FACS analysis. GFP, green fluorescent protein; GM-CSF, granulocyte-macrophage colony-stimulating factor; FACS, fluorescence-activated cell sorting; IL-3, interleukin-3; SCF, stem cell factor; shRNA, short hairpin RNA.
Letters to the Editor the transcription apparatus but also binding and inhibiting the E2F complex, an important regulator of cell-cycle progression. 1 Thus, it would be predicted that p30 has lost important functional attributes necessary for driving myelocytic differentiation, including regulation of lineage-specific genes and the induction of growth arrest that occurs at the metamyelocytic stage of differentiation. Furthermore, the reported dominant-negative activity of p30 on the transcriptional function of wt C/EBPa, presumably through the formation of heterodimerization, would also limit the activity of the non-mutated CEBPA allele. 6 Somewhat surprisingly, we have shown earlier that ectopic p30 expression in murine myeloid progenitors induces myeloid differentiation, albeit with altered proliferation kinetics. 5 A recent study has confirmed these results; mice engineered to heterozygously express p30 from the Cebpa allele display normal granulopoiesis. 7 Notably, however, mice homozygous for this altered allele develop AML with a penetrance of 100%. One interpretation is that the p30 form is indeed still able to drive the transition to the GM progenitor stage and that its inability to efficiently regulate cell cycle control through E2F leads to a myeloproliferation, which progresses into AML.
Does the same mechanism apply to humans? In our earlier study, we noted that enforced p30 expression in human (versus murine) progenitors actually resulted in a profound block in myeloid differentiation. 5 This difference could not be attributed to species-specific attributes of the protein, as both murine and human proteins showed similar effects. To obtain insight into the mechanism by which p30 inhibits myeloid differentiation in human hematopoietic cells, we analyzed different dimerizing mutants of p30, as well as investigated the effect of knocking down CEBPA expression on human myelopoiesis using short hairpin RNA technology.
The highly conserved basic leucine zipper domain at the C terminus of all C/EBP proteins contains a basic charged domain that mediates DNA binding and a ZIP domain necessary for dimerization, the latter being indispensable for both DNA-binding and transactivation activity. To evaluate the requirement for dimerization of p30 to block myeloid Letters to the Editor differentiation, a mutant was generated in which the first two leucines of the ZIP domain were replaced by valine (p30-L12V), which has been shown earlier to disrupt C/EBPa function. 8 In a second construct, the ZIP domain of p30 was exchanged with that of the yeast GCN4 regulatory protein to form p30-GZ, which allows p30 homodimerization but not heterodimerization with other C/EBP proteins.
CD34
þ cells isolated from human cord blood were transduced with retroviral vectors (FEMV-GFP) expressing either GFP alone or together with p30, p30-L12V or p30-GZ, and then sorted for green fluorescent protein expression, as described earlier. 5 The myeloid and erythroid differentiation potentials of these different transduced cells were assessed by either plating into methylcellulose or keeping them in liquid cultures supplemented with a cytokine cocktail that supports differentiation. Cells infected with either the control vector or the vector expressing p30-L12V developed similar numbers of both typical myeloid and erythroid colonies initiated by colony-forming units (CFU)-GM and blast-forming units-erythroid (BFU-E), respectively. In contrast, both p30 and p30-GZ expression induced almost exclusively colonies that were composed of immature cell types (Figure 1a) . Examination of cytospins from these colonies confirmed that the p30 and p30-GZ colonies were primarily composed of myeloblasts and neutrophilic myelocytes, in contrast to the predominant macrophage and erythroid cells within the control colonies and colonies derived from p30-L12V cultures (Figure 1b) . Thus p30-GZ, as well as p30 but not p30-L12V, appears to not only inhibit the development of mature myeloid forms but also redirect erythroid-committed cells to the myeloid lineage (as evidenced by the loss of BFU-E colonies), which has also been observed after ectopic expression of wt C/EBPa. 9 However, the suppression of the erythroid program appears not to be complete, as we have shown earlier that these cells coexpress erythroid (glycophorin A) and myeloid (myeloperoxidase) markers. 5 Liquid cultures supporting myeloid differentiation confirmed the impaired myeloid differentiation program. Although p30 and p30-GZ cultures appeared to initially differentiate more rapidly as control cultures (reflected in the rapid loss of CD34 expression at day 7; Figure 1c ), analysis at day 14 showed that the majority of cells failed to complete the differentiation program, as assessed by the continued expression of the early myeloid marker CD33 and the relatively low number of cells expressing markers of more mature monocytic or granulocytic cells, such as CD14 and CD15 on day 14 (Figure 1c) .
Taken together, these results demonstrate that p30 is able to drive the initial phases of human myeloid differentiation by a mechanism requiring dimerization, and thus DNA binding and/or transactivation activity. However, p30 is unable to promote the final stages of differentiation, which are coupled with growth arrest and differential regulation of lineage-specific genes. This does not involve the formation of heterodimers and functional inactivation of other C/EBP proteins, as p30-GZ, which can only form homodimers, also inhibits differentiation at the myeloblast/ myelocyte stage. In contrast, p30 expression in mouse progenitors is able to both induce myeloid differentiation and permit end-stage maturation, either when ectopically expressed or when expressed in situ. 5, 7 A likely explanation for this discrepancy would be that in the mouse, alternative pathways are available to regulate the transition from common myeloid progenitor to GM progenitor, even if C/EBPa-binding sites or interacting proteins are occupied by high (or normal) levels of p30.
To assess if the striking difference between the effect of p30 expression on human and mouse myelopoiesis reflects an inherent difference in the importance of C/EBPa in myelopoiesis, we evaluated the effect of downregulation of CEBPA expression by small interference RNA. A short hairpin sequence specific for CEBPA (and not other CEBP genes; Figure 2a ) was cloned into a retroviral expression vector (RSG-SIN) coexpressing green fluorescent protein. The efficiency of C/EBPa downregulation was first tested in a cell line (Figure 2b ) and then introduced into human CD34 þ cells. A greater than 80% reduction of CEBPA transcript levels was observed 36 h after infection, as measured by quantitative reverse transcriptase PCR (Figure 2c ). CEBPB transcripts were not reduced in these cells; indeed slightly higher levels were observed (data not shown). After 7 days, liquid cultures expressing shCEBPA consistently contained circa 30% fewer cells and showed a relative increase in erythroid cells (CD13 À CD71 þ ) as compared with myeloid cells (CD13 þ /CD71 À ) (Figure 2d ), reflecting an impaired proliferation of differentiating myeloid cells. To judge better the differentiation potential of these cells, methylcellulose cultures were used, in which differentiation is initiated from a few clonogenic cells. A dramatic reduction in not only CFU-GM colonies (containing predominantly immature cell types) but also BFU-E colonies was observed in cultures receiving short hairpin RNA against CEBPA transcripts (Figure 2e) . Notably, the CFU-GM colonies were also noticeably smaller than control CFU-GM colonies, consistent with the reduced proliferation of committed cells. Microscopic evaluation of dispersed cells from the colonies showed that whereas erythroid differentiation was otherwise unperturbed, an almost complete block in terminal differentiation of GM progenitors was observed in cultures receiving shCEBPA (Figure 2f) . Strikingly, both the reduction in CFU-GM colony numbers and a terminal block in GM differentiation were observed with GM colony-stimulating factor or granulocyte colony-stimulating factor (Figures 2g and h) , which is in striking contrast to results obtained from Cebpadeficient mice. 3 It was unexpected that the downregulation of CEBPA would also affect the generation of progenitors committed to the erythroid lineage (BFU-E). In studies using both mouse and human cells, ectopic C/EBPa expression has been reported to inhibit erythropoiesis. However, results from Cebpa-deficient mouse models are less clear; both an increase and no change in the number of erythroid progenitors have been reported. 3 Notably, microarray analysis shows that CEBPA is expressed in early non-committed CD34 þ cells but not early erythroid progenitors (CD71 þ ) in human bone marrow (http://genome. ucsc.edu/cgi-bin/hgNear). It is thus likely that the reduction of CEBPA transcripts does not directly impinge on BFU-E, but on myeloid-erythroid (or earlier) progenitors. The importance of CEBP/a in this very early cell type clearly needs to be investigated further.
The block to granulocytic and monocytic differentiation observed when CEBPA transcripts are downregulated was not unexpected, but striking in that no cytokine tested was able to overcome the block. This clearly shows that C/EBPa activity is not readily substituted by alternative pathways in human myeloid differentiation. Notably, this does not mean that other C/EBP proteins (for example, C/EBPb, C/EBPd and C/EBPe) are not necessary in this process, but that their activity may be tightly regulated by C/EBPa directly. 3, 5 Indeed expression profiling during granulocytic differentiation in human bone marrow shows a clear overlap in the expression of these factors during the transition of myeloblasts through myelocytes/ metamyelocytes to more mature (banded and segmented) forms. 10 Conceivably, the inability of p30 to activate one or several of the human genes encoding other C/EBP proteins may explain the observed block in our system. A more extensive analysis of the different C/EBP family members in regulating both gene transcription and growth arrest in human myelopoiesis is required to understand better the mechanisms at play.
Our observations also shed light on another discrepancy between findings in mouse models and analysis of AML patient samples. In addition to genetic mutations that directly impact the CEBPA gene, leading to truncated C/EBPa forms, several studies have also revealed mechanisms by which either C/EBPa transcript or protein levels are greatly reduced in AML patients (for example, by promoter hypermethylation or by inhibition of transcription or translation by leukemia-specific fusion proteins) or C/EBPa is functionally inactivated (for example, phosphorylation by activated FLT3.) 1 These results would suggest that reduced levels of C/EBPa may be sufficient to impair myeloid differentiation, a hypothesis reinforced by our resultsFbut not observed in Cebpa þ /À mouse models. In summary, our results underline the critical role of C/EBPa in human myelopoiesis, distinct to that observed in murine myelopoiesis, which correlates with its frequent deregulation in AML. We would like to emphasize that although knockdown and ectopic expression analyses in mouse systems have provided, and will certainly continue to provide, essential insights into normal hematopoiesis and leukemogenesis, the limitations of these models should not be overlooked.
